The week of February 15–21, 2026 recorded approximately $16.5 billion in aggregate announced transaction value across 35+ discrete events.

When Agios Pharmaceuticals sold its vorasidenib royalty to Royalty Pharma for $905m in 2024, a single buyer wrote the entire

Iambic Therapeutics is a San Diego-based clinical-stage biotechnology company using physics-informed artificial intelligence to discover and develop novel small-molecule drugs, primarily in oncology.

How the National Kidney Foundation is betting venture philanthropy can transform kidney care — and what could go wrong.

Step-in rights are contractual provisions allowing one party to assume operational control when the counterparty fails to perform. In pharmaceutical

How the analytical tools of pharmaceutical royalty finance — risk-adjusted NPV, probability weighting, decay curves, and defensibility analysis — translate directly to pricing healthcare data assets. And why the market may be mispricing them right now.

A court ruling in New York has settled a question that most executives never thought to ask. The answer should worry anyone who has ever pasted something sensitive into Claude or ChatGPT.

Biotech and Healthcare Transactions: Week of February 8–14, 2026 The week of February 8–14, 2026 recorded over $25

When Innoviva moved to acquire La Jolla Pharmaceutical in 2022, the transaction revealed a hidden tripwire that many biotech M&

Overview of Epidarex Capital and Strategy Epidarex Capital is a transatlantic venture capital firm focused on early-stage life science and